TITLE

Medical oncology

PUB. DATE
August 1997
SOURCE
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS58
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Presents an abstract of the research manuscript `Improved results of salvage therapy for germ cell cancer (GCC) using VIP and/or VeIP to maximal response followed by high-dose chemotherapy (HDCT) with autologous marrow or stem cell rescue,' by E. Winquist et al. Bone marrow and stem cell transplantation.
ACCESSION #
9708236626

 

Related Articles

  • Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Broun, E. Randolph; Nichols, Craig R.; Kneebone, Patricia; Williams, Stephen D.; Lochrer, Patrick J.; Emhorn, Lawrence H.; Tricol, Guido J. K.; Broun, E R; Nichols, C R; Kneebone, P; Williams, S D; Loehrer, P J; Einhorn, L H; Tricot, G J // Annals of Internal Medicine;7/15/92, Vol. 117 Issue 2, p124 

    Objective: To review the long-term outcome of patients with recurrent and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue.Design: Cohort study.Setting: A university hospital.Patients: Forty...

  • Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. Kröger, N; Hoffknecht, M; Dreger, P; Krüger, W; Zeller, W; Krüll, A; Stockschläder, M; Bittner, S; Weh, H J; Zander, A R // Bone Marrow Transplantation;1/1/98, Vol. 21 Issue 1, p55 

    In advanced stage mantle cell lymphoma, conventional chemotherapy yields a complete remission rate below 40%, and the median survival rate is only about 3 years. Between 1991 and 1996 we treated nine such patients (six male; three female) with high-dose chemotherapy (six of these also with 12 Gy...

  • Computer-based quality control in high-dose chemotherapy and bone marrow transplantation. Bornhäuser, M; Schmidt, M; Ehninger, U; von Keller, J; Schuler, U; Ehninger, G // Bone Marrow Transplantation;3/1/98, Vol. 21 Issue 5, p505 

    High-dose chemotherapy with autologous and allogeneic blood stem cell transplantation has become a standard therapy for hematological malignancies and solid tumors. To ensure quality of treatment and adherence to internationally approved protocols, the use of computer systems has been introduced...

  • Reduced charges and costs associated with outpatient autologous stem cell transplantation. Meisenberg, B.R.; Ferran, K.; Hollenbach, K.; Brehm, T.; Jollon, J.; Piro, L.D. // Bone Marrow Transplantation;5/1/98, Vol. 21 Issue 9, p927 

    High-dose chemotherapy and stem cell rescue is increasingly being delivered in the outpatient setting. Such intensive outpatient management programs have reduced the total hospital length of stay without compromising clinical outcomes. However, a detailed financial analysis of outpatient...

  • Palliative care in BMT. Chung, H. M.; Lyckholm, L. J.; Smith, T. J. // Bone Marrow Transplantation;Feb2009, Vol. 43 Issue 4, p265 

    The field of high-dose therapy and SCT has made many advances in the past several years and the success rates have been steadily increasing as newer therapies emerge and improvements in supportive care continue to improve patient survival and cure rates. There still remains a mortality risk for...

  • Prognostic impact of diffuse large B-cell lymphoma subgroups in patients undergoing autologous SCT. Hallack Neto, A. E.; Dulley, F. L.; Coelho Siqueira, S. A.; Pracchia, L. F.; Belesso, M.; Saboya, R.; Sturaro, D.; Amigo-Filho, J. U.; Mendrone Junior, A.; Chamone, D. A. F.; Pereira, J. // Bone Marrow Transplantation;Feb2009, Vol. 43 Issue 4, p323 

    A total of 53 patients aged 18–60 years with high-intermediate or high-risk diffuse large B-cell lymphoma (DLBCL) were evaluated to analyze the impact of the cell of origin. Of 53 patients, 16 underwent autologous SCT (ASCT) in first remission and the rest received conventional...

  • BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: comparative analysis of efficacy and toxicity. Jae-Cheol Jo; Byung Kang; Geundoo Jang; Sun Sym; Sung Lee; Ja Koo; Jong Kim; Shin Kim; Jooryung Huh; Cheolwon Suh // Annals of Hematology;Jan2008, Vol. 87 Issue 1, p43 

    The treatment of choice for relapsed/refractory non-Hodgkin’s lymphoma (NHL) consists of high-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT). Little is known, however, regarding the comparative toxicity and efficacy of various HDC regimens applied in NHL....

  • Ovarian recovery after stem cell transplantation. Liu, J.; Malhotra, R.; Voltarelli, J.; Stracieri, A. B.; Oliveira, L.; Simoes, B. P.; Ball, E. D.; Carrier, E. // Bone Marrow Transplantation;Feb2008, Vol. 41 Issue 3, p275 

    Autologous or allogeneic SCT with conventional conditioning (chemotherapy with or without irradiation) has emerged as an effective and potentially curative therapy in patients with hematologic malignancies and in other selected solid tumors; however, several patients experience significant early...

  • Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome. Kimiskidis, V. K.; Sakellari, I.; Tsimourtou, V.; Kapina, V.; Papagiannopoulos, S.; Kazis, D.; Vlaikidis, N.; Anagnostopoulos, A.; Fassas, A. // Multiple Sclerosis (13524585);Mar2008, Vol. 14 Issue 2, p278 

    Malignant multiple sclerosis (MS) is a rare but clinically important subtype of MS characterized by the rapid development of significant disability in the early stages of the disease process. These patients are refractory to conventional immunomodulatory agents and the mainstay of their...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics